Press Releases

    • MAY 22 2017

    Cell Cycle Article Describes Anti-Cancer Efficacy of Imipridones

    Philadelphia, PA (May 18, 2017) – Oncoceutics, Inc. announced that the journal Cell Cycle recently published a manuscript detailing the anti-cancer efficacy of members of the imipridone family. The publication, from the laboratory of Wafik El-Deiry MD, PhD, FACP, Scientific Founder of Oncoceutics, and Deputy Cancer Center Director for Translational Research of the Fox Chase

    • MAY 08 2017

    Research Publications Provide Rationale for ONC201 Trials in Breast Cancer

    Philadelphia, PA (May 4, 2017) – Recently, Oncoceutics collaborators have published two research articles demonstrating that Oncoceutics’ lead imipridone, ONC201, shows anti-tumor efficacy in preclinical models in several distinct subtypes of breast cancer, including triple-negative breast cancer (TNBC). TNBC, so called because its growth is not supported by estrogen, progesterone, or HER2, is a particularly

    • APR 27 2017

    Fox Chase Enrolling Patients in ONC201 Multiple Myeloma Trial

    Philadelphia, PA (April 27, 2017) – Oncoceutics, Inc. announced that the first patient has begun treatment in a clinical trial of the company’s lead compound, ONC201, at the Fox Chase Cancer Center (FCCC) in relapsed/refractory multiple myeloma. The Phase I/II trial, identified as NCT02863991 on, will investigate the use of ONC201 in combination with

    • MAR 29 2017

    MGH/Dana Farber Initiate Expansion of ONC201 Glioblastoma Trial

    Philadelphia, PA (March 29, 2017) – Oncoceutics, Inc. announced that Massachusetts General Hospital (MGH) and the Dana Farber Cancer Institute are now enrolling patients in an expansion of the clinical trial “Oral ONC201 in Adult Recurrent Glioblastoma”. The Phase II Trial, identified as NCT02525692 on, began in early 2016 with recurrent glioblastoma (GBM) patients